A human monoclonal antibody, bezlotoxumab 10 mg / kg IV given once, binds to and neutralizes C difficile toxin B; it can be used for prevention of recurrent C difficile - induced diarrhea along with standard-of-care treatment in patients who have had a recurrence within the last 6 months.